Intravenous Fosfomycin for Gram-Negative and Gram-Positive Bacterial Infections: A Systematic Review of the Clinical Evidence.

Matthew E Falagas, Dimitrios S Kontogiannis, Laura T Romanos, Dimitrios Ragias, Maria Eleni Agoranou, Stylianos A Kakoullis

Abstract readReview

PubMed Full text at PMC Publisher

In one paragraph

Review in Antibiotics (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it

0cells of the map it votes in

4citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

Real-World Data on the Effectiveness and Use of Intravenous Fosfomycin for the Treatment of Difficult-to-Treat Infections Caused by Carbapenem-Resistant Gram-Negative Bacteria-A Subgroup Analysis from the FORTRESS Study.Infectious diseases and therapy · 2026
Article
Antimicrobial Stewardship, Laboratory Surveillance, and Quality Management in Africa: A Narrative Review of Challenges and Opportunities for Integrated AMR Control.Health science reports · 2026
Article
From Environmental Organism to Nosocomial Threat:Antibiotics (Basel, Switzerland) · 2026
Review
Fosfomycin Use in Treating Severe Difficult-to-Treat Gram-Negative Infections-A Comprehensive Review.Antibiotics (Basel, Switzerland) · 2026
Review

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Matthew E FalagasAlfa Institute of Biomedical Sciences (AIBS), 151 23 Athens, Greece.

Dimitrios S KontogiannisAlfa Institute of Biomedical Sciences (AIBS), 151 23 Athens, Greece.

Laura T RomanosAlfa Institute of Biomedical Sciences (AIBS), 151 23 Athens, Greece.

Dimitrios RagiasAlfa Institute of Biomedical Sciences (AIBS), 151 23 Athens, Greece.

Maria Eleni AgoranouAlfa Institute of Biomedical Sciences (AIBS), 151 23 Athens, Greece.

Stylianos A KakoullisSchool of Medicine, European University Cyprus, 2404 Nicosia, Cyprus.

Funding

InfectoPharm Arzneimittel und Consilium GmbH, Heppenheim, Germany Non-available

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Acinetobacter baumanniicombination therapyEnterobacteralesEnterococcusfosfomycinGram-negative bacteriaGram-positive bacteriaKlebsiella pneumoniaePseudomonas aeruginosaStaphylococcus aureus

Identifiers

PMID41463696

DOI10.3390/antibiotics14121193

PMCPMC12729521

What Socratic holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.